NY-ESO-SPEAR T-cell therapy: Ph I/II started

Adaptimmune began an open-label, U.S. Phase I/II trial to evaluate a single IV infusion of NY-ESO-SPEAR T-cell therapy following

Read the full 192 word article

User Sign In